Myasthenia gravis (MG), Lambert-Eaton myasthenic syndrome (LEMS), and congenital
myasthenic syndromes (CMS) represent an etiologically heterogeneous group of (very) rare …

Recent advances in the understanding of autoantibody functionalities are bringing
neuroimmunologists closer to a more detailed appreciation of the mechanisms that govern …

Myasthenia gravis (MG) is a chronic autoimmune disease mediated by antibodies against
post-synaptic proteins of the neuromuscular junction. Up to 10%–30% of patients are …

Introduction Myasthenia gravis (MG) is caused by IgG antibodies against different proteins at
the neuromuscular junction. Anti-acetylcholine receptor (AChR) Abs are detected in the …

Background Lymphoplasmapheresis (LPE) is a treatment that combines traditional plasma
exchange and lymphocyte removal technique. It has been applied to treat a variety of …

Abstract B cell-directed CAR T cell therapy has fundamentally changed the treatment of
hematological malignancies and its scope of application is rapidly expanding to include …

Cognitive impairment in later life can be caused by one or more neurodegenerative
diseases or by cerebrovascular disease, in various combinations. Fluid and imaging …

Objectives Patients with refractory myasthenia gravis (MG) have few treatment options.
Autologous hematopoietic stem cell transplantation (HSCT) has been used to treat immune …

Myasthenia gravis (MG) is a rare, autoimmune, neurological disorder. Most MG patients
have autoantibodies against acetylcholine receptors (AChRs). Some have autoantibodies …

Myasthenia gravis (MG) is an antibody-mediated autoimmune disease with a prevalence of
150–250 cases per million individuals. Autoantibodies include long-lived antibodies against …